Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan-Reference-Cited by-同舟云学术

Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan

Published:2021-03-06 Issue:2 Volume:15 Page:338-349
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Liu Chen-Hua,Chen Po-Yueh,Chen Jyh-Jou,Lo Ching-Chu,Su Wei-Wen,Tseng Kuo-Chih,Liu Chun-Jen,Huang Chia-Sheng,Huang Ke-Jhang,Yang Sheng-Shun,Peng Cheng-Yuan,Tsai Ming-Chang,Kao Wei-Yu,Chang Chi-Yang,Shih Yu-Lueng,Fang Yu-Jen,Chen Chi-Yi,Lee Pei-Lun,Huang Jow-Jyh,Su Pei-Yuan,Tseng Chi-Wei,Hung Chien-Ching,Chang Chung-Hsin,Huang Yi-Jie,Lai Hsueh-Chou,Chang Chun-Chao,Lee Fu-Jen,Hsieh Tsai‐Yuan,Kao Jia-Horng^ORCID

Funder

Ministry of Science and Technology, Taiwan

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

https://link.springer.com/content/pdf/10.1007/s12072-021-10158-x.pdf

Reference30 articles.

1. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161–176

2. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, R.E.V.E.A.L.-HCV Study Group, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206:469–477

3. Younossi ZM, Henry L, Pong J, Tanaka A, Eguchi Y, Mizokami M, et al. Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia. Aliment Pharmacol Ther 2019;49:644–653